A method of treating Type 2 diabetes (T2D) is provided. The method includes administering to a subject in need thereof an effective amount of a pharmaceutical composition that includes an insulin-transferrin fusion protein or its prodrug, proinsulin-transferrin fusion protein.

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

[Problem] To provide a novel artificial protein catalyst that enables the protection of a catalyst from substances in vivo and has potential usefulness in therapeutic in vivo synthetic chemistry.

[Solution] Provided is a complex of a protein and a catalyst selected from a metal catalyst or organic catalyst. In the complex according to the present invention, the protein is a protein having a hydrophobic pocket in the three-dimensional structure thereof, and the catalyst is housed in the hydrophobic pocket so that the catalyst is not or substantially not exposed to a hydrophilic environment.

[Problem] To provide a novel artificial protein catalyst that enables the protection of a catalyst from substances in vivo and has potential usefulness in therapeutic in vivo synthetic chemistry.

[Solution] Provided is a complex of a protein and a catalyst selected from a metal catalyst or organic catalyst. In the complex according to the present invention, the protein is a protein having a hydrophobic pocket in the three-dimensional structure thereof, and the catalyst is housed in the hydrophobic pocket so that the catalyst is not or substantially not exposed to a hydrophilic environment.

Provided herein are recombinant animal-free food compositions comprising egg-white proteins such as ovalbumin, ovotransferrin and lysozyme and methods of making such food compositions.

Provided herein are recombinant animal-free food compositions comprising egg-white proteins such as ovalbumin, ovotransferrin and lysozyme and methods of making such food compositions.

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

The present disclosure provides methods of modulating an immune response in an individual. The present disclosure provides methods of treatment. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) and an immune checkpoint inhibitor to an individual. The present disclosure provides methods comprising administering a multimeric polypeptide (synTac) to an individual who is undergoing treatment with immune checkpoint inhibitor.

The invention relates to molecular biology, biotechnology, medicine, veterinary science. A group of inventions is proposed: a fusion protein comprising a ligand to MATN1 protein, and a growth factor of EGF, TGF, FGF, IGF, connected via a flexible link; such fusion protein further comprising the Fc-fragment of an antibody or a polypeptide binding with FcRn and/or transferrin or a fragment thereof, connected via a flexible link; encoding polynucleotide, a genetic construct for the synthesis of the fusion protein in producer cells, or cells of a target organism, the fusion protein producer, a producer of the genetic construct, a preparation for the regeneration of cartilage containing at least 1 fusion protein or genetic construct, for parenteral or, in the case of the preparation based on at least 1 fusion protein containing the transport domain, —oral administration, in the latter case the preparation is enclosed in an enteric coating.